The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
Chuikyo OKs Plan for September Drug Price Survey, Smaller Coverage amid COVID-19
A key Japanese reimbursement policy panel on July 22 approved a plan to conduct a drug price survey covering transactions in September 2020 for “off-year” re-pricing scheduled for next April. The number of wholesalers and healthcare providers that will be…
To read the full story
Related Article
- With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
- September Drug Price Survey Likely as MHLW to Keep Its Proposal Unchanged
July 21, 2020
- Japan Govt Adopts 2020 Honebuto Policy, Drug Price Survey to Be Conducted This Autumn
July 17, 2020
- MHLW Delays Chuikyo Discussion Timeline for Off-Year Price Survey, Drops June-End Goal
June 22, 2020
- Chuikyo Doctor Reps Nix Drug Price Survey Discussion, Say It Should Only Come after Govt’s Go/No-Go Decision
June 18, 2020
- MHLW to Propose Two-Third Sampling Rate for Wholesaler Survey for Off-Year Drug Re-Pricing; Go/No-Go Debate to Continue
June 16, 2020
- Industry Says There’s No Way Off-Year Drug Price Survey Can Be Done; Chuikyo Healthcare Reps Agree but Payers Don’t
June 11, 2020
REGULATORY
- Japan Panel to Review Pfizer’s Cancer Med Tukysa on January 29
January 16, 2026
- Study Group Calls for Independent Body to Centrally Manage Whole Genome Data
January 16, 2026
- Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
January 16, 2026
- Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
- MHLW Orders Label Revisions for Aspirin, CAR-T Therapies, and Other Drugs
January 14, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…